Evidence map›Paper›PMID 26512954›Full record

ArticleCell death & disease2015

NBR1 is dispensable for PARK2-mediated mitophagy regardless of the presence or absence of SQSTM1.

J Shi, G Fung, H Deng, J Zhang, F C Fiesel, W Springer, X Li, H Luo

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. The Dawn of Mitophagy: What Do We Know by Now?Current neuropharmacology · 2021
    Review
  13. Article
  14. Mitophagy and the Brain.International journal of molecular sciences · 2020
    Review
  15. Mitophagy pathways in health and disease.The Journal of cell biology · 2020
    Review
  16. Decision between mitophagy and apoptosis by Parkin via VDAC1 ubiquitination.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  17. Article
  18. Review
  19. The Marine DinoflagellateMarine drugs · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

J ShiDepartment of Pathology and Laboratory Medicine, James Hogg Research Center, Providence Heart+Lung Institute, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
G FungDepartment of Pathology and Laboratory Medicine, James Hogg Research Center, Providence Heart+Lung Institute, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
H DengDepartment of Pathology and Laboratory Medicine, James Hogg Research Center, Providence Heart+Lung Institute, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
J ZhangDepartment of Pathology and Laboratory Medicine, James Hogg Research Center, Providence Heart+Lung Institute, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
F C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
W SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
X LiDepartment of Biochemistry and Molecular Biology, Institute of Biomedical Sciences, East China Normal University, Shanghai, China.
H LuoDepartment of Pathology and Laboratory Medicine, James Hogg Research Center, Providence Heart+Lung Institute, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CAMayo Clinic · USSt. Paul's Hospital · CABaylor College of Medicine · US

Funding

Molecular mechanisms of Parkin-directed mitochondrial quality controlR01NS085070 · NINDS · MAYO CLINIC JACKSONVILLE · PI SPRINGER, WOLFDIETER · 2014 to 2018
$1.7M
Canadian Institutes of Health Research CCI-125685Canadian Institutes of Health Research MOP-119274NINDS NIH HHS R01 NS085070
6 · The paper itself

Abstract

Degradation of malfunctional mitochondria by mitophagy is a pivotal component of mitochondrial quality control to maintain cellular homeostasis. Mitochondrial clearance through the PINK1/PARK2 pathway is mediated by autophagic adaptor proteins. Previous studies revealed a significant involvement, but not an absolute requirement for SQSTM1 in PARK2-dependent mitophagy, suggesting that the existence of redundant adaptor proteins may compensate for the loss of SQSTM1. Here we investigated whether NBR1, a functional homolog of SQSTM1, has a role in PARK2-mediated mitophagy, either alone or as a compensatory mechanism. We showed that NBR1 does not appear to be required for mitochondrial clustering following mitochondrial depolarization. Moreover, we demonstrated that deletion of NBR1 alone or in combination with SQSTM1 does not prevent the degradation of damaged mitochondria. Our data suggest that NBR1 is dispensable for PARK2-dependent mitophagy and additional autophagic adaptor proteins, other than NBR1, are responsible for mitochondrial degradation in cells depleted of SQSTM1.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCarbonyl Cyanide m-Chlorophenyl HydrazoneCells, CulturedGene DeletionHeLa CellsHumansIntracellular Signaling Peptides and ProteinsMitophagyProteinsSequestosome-1 ProteinUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingCarbonyl Cyanide m-Chlorophenyl HydrazoneIntracellular Signaling Peptides and ProteinsNBR1 protein, humanparkin proteinProteinsSequestosome-1 ProteinSQSTM1 protein, humanUbiquitin-Protein Ligases

Identifiers

PMID26512954
PMCPMC4632303
OpenAlexW2139446098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.